Scancell Limited
Scancell Limited
Trading as: Scancell
#03234881 • Active
B2bPhysical ProductServices
Scancell is a clinical stage biopharmaceutical company dedicated to developing innovative immunotherapies that harness the body's immune system to combat cancer and infectious diseases. Their proprietary research focuses on creating novel vaccines and monoclonal antibodies targeting specific protein modifications.
Founded: 07/08/1996
Industries: Research and experimental development on biotechnology
Website: https://scancell.co.uk
Phone: Subscribe to view
Email: Subscribe to view
Location: Oxford
Products
- Avidimab® Antibody Enhancement Platform
- Glymab® Monoclonal Antibodies
- Immunobody® Vaccines
- Moditope® Cancer Vaccines
Services
- Immunotherapy Development
- Monoclonal Antibody Production
- Vaccine Development
Financial Snapshot
Last accounts made up to 30 April 2024
Next accounts due 31 January 2026 (8 months)
Cash in Bank £0.85m
↓ -89%
EBITDA -£16.7m
↓ 51%
Total Liabilities £11.83m
↑ 285%
Employees 61
↑ 20%
Directors
Name | Role | Appointed ↓ | Nationality | Age |
|---|---|---|---|---|
| Phillip John L’huillier | Chief Executive Officer | 18/11/2024 | New Zealander | 63 years |
| Sathijeevan Nirmalananthan | Chartered Accountant | 14/03/2024 | British | 39 years |
| Linda Gillian Durrant | Scientist | 20/08/1996 | British | 67 years |
Role:
Chief Executive Officer
Appointed:
18/11/2024
Nationality:
New Zealander
Age:
63 years
Role:
Chartered Accountant
Appointed:
14/03/2024
Nationality:
British
Age:
39 years
Role:
Scientist
Appointed:
20/08/1996
Nationality:
British
Age:
67 years
People with Significant Control
| Name | Nature of Control | Notified On | Nationality |
|---|---|---|---|
| Scancell Holdings Plc | Ownership Of Shares 75 To 100 Percent, Voting Rights 75 To 100 Percent, Right To Appoint And Remove Directors, Significant Influence Or Control | 06/04/2016 | United Kingdom |
Nature of Control:
Ownership Of Shares 75 To 100 Percent, Voting Rights 75 To 100 Percent, Right To Appoint And Remove Directors, Significant Influence Or Control
Notified On:
06/04/2016
Nationality:
United Kingdom
Financial Accounts
| Apr 2024 | Apr 2023 | Apr 2022 | |
|---|---|---|---|
| Income Statement | |||
| Turnover | |||
| Export Revenue | |||
| Sales | |||
| Other Operating Income | |||
| Other Operating Items | |||
| Cost of Sales | |||
| Raw Materials & Consumables | |||
| Gross Profit | |||
| Admin Expenses | |||
| Other Operating Charges | |||
| Depreciation | |||
| R&D Expenses | |||
| Operating Profit | |||
| EBITDA | |||
| Financial Revenue | |||
| Financial Expenses | |||
| Financial Profit/Loss | |||
| Interest Paid | |||
| Extraordinary Revenue | |||
| Extraordinary Expenses | |||
| Net Extraordinary Items | |||
| Pre-Tax Profit | |||
| Tax | |||
| Profit After Tax | |||
| Retained Profit | |||
| Balance Sheet | |||
| Non-Current Assets | |||
| Intangible Assets | |||
| Tangible Fixed Assets | |||
| Other Non-Current Assets | |||
| Current Assets | |||
| Stock | |||
| Debtors | |||
| Cash in Hand | |||
| Other Current Assets | |||
| Called Up Share Capital | |||
| P&L Account Reserve | |||
| Shareholder Funds | |||
| Other Shareholder Funds | |||
| Provisions | |||
| Long Term Debt | |||
| Creditors (> 1 year) | |||
| Other Non-Current Liabilities | |||
| Short Term Debt | |||
| Creditors | |||
| Creditors (< 1 year) | |||
| Other Current Liabilities | |||
| Key Metrics | |||
| Net Assets | |||
| Net Current Assets | |||
| Total Assets Less Current Liabilities | |||
| Working Capital | |||
| Enterprise Value | |||
| Added Value | |||
| Cashflow Before D&A | |||
| Other Information | |||
| Staff Costs | |||
| Number of Employees | |||
Charges
No charges registered
Properties
No property information available
Grants
Total grant funding received: £1,882,942.60
| Programme | |||
|---|---|---|---|
| 01/10/2020 | £1,882,942.60 | Department for Business, Energy and Industrial Strategy | ALB - UKRI - Innovate UK grant awards in 20-21 |
| Full Grant details (including summaries) can be found on the Gateway to Research website: https://gtr.ukri.org/projects?ref=73437 | |||
Department for Business, Energy and Industrial Strategy
£1,882,942.60Full Grant details (including summaries) can be found on the Gateway to Research website: https://gtr.ukri.org/projects?ref=73437
Date Awarded:
01/10/2020
Programme:
ALB - UKRI - Innovate UK grant awards in 20-21
Government Council Contracts Beta
No council contracts found
Company Filings
| Date | Category | Description | Document |
|---|---|---|---|
| 15/04/2025 | Officers | Change Person Director Company With Change Date | View (2 pages) |
| 08/01/2025 | Accounts | Accounts With Accounts Type Full | View (30 pages) |
| 21/11/2024 | Officers | Appoint Person Director Company With Name Date | View (2 pages) |
| 30/07/2024 | Confirmation Statement | Confirmation Statement With No Updates | View (3 pages) |
| 23/05/2024 | Officers | Appoint Person Secretary Company With Name Date | View (2 pages) |
| 23/05/2024 | Officers | Termination Secretary Company With Name Termination Date | View (1 page) |
| 15/03/2024 | Officers | Appoint Person Director Company With Name Date | View (2 pages) |